Clinical Trial Update: Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating icotinib plus dihydroaremisinin (DHA) in EGFR-positive non-small cell lung cancer with adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• dihydroaremisinin (DHA) (dihydroaremisinin)
• icotinib (icotinib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma | Phase 2 | Status: UNKNOWN